Breaking News, Collaborations & Alliances, Trials & Filings

Arzerra sBLA for CLL Gets Priority Review status

GSK, Genmab biologic gets PDUFA date of April 19, 2014

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

GlaxoSmithKline and Genmab have received Priority Review designation from the FDA for the sBLA for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of chronic lymphocytic leukemia (CLL) patients who have not received prior treatment and are inappropriate for fludarabine-based therapy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of April 19, 2014 for the sBLA for Arzerra. Ofatumumab is not approved or licensed ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters